Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.17 USD | -2.82% | -13.61% | +1.88% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 790M |
---|---|---|---|---|---|
Net income 2024 * | -158M | Net income 2025 * | -166M | EV / Sales 2024 * | - |
Net Debt 2024 * | 952K | Net Debt 2025 * | 13.89M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.22
x | P/E ratio 2025 * |
-5.26
x | Employees | 72 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.33% |
Latest transcript on ALX Oncology Holdings Inc.
1 day | -2.82% | ||
1 week | -13.61% | ||
Current month | -10.87% | ||
1 month | +16.42% | ||
3 months | -4.23% | ||
6 months | +71.80% | ||
Current year | +1.88% |
Managers | Title | Age | Since |
---|---|---|---|
Jaume Pons
FOU | Founder | 58 | 15-03-31 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 20-03-31 |
Peter García
DFI | Director of Finance/CFO | 62 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
J. Garland
BRD | Director/Board Member | 55 | 22-11-27 |
Corey Goodman
CHM | Chairman | 72 | 15-02-28 |
Jason Lettmann
CEO | Chief Executive Officer | 46 | 20-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +9.94% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 15.17 | -2.82% | 385,283 |
24-05-13 | 15.61 | -3.70% | 438,228 |
24-05-10 | 16.21 | -4.37% | 388,639 |
24-05-09 | 16.95 | +2.05% | 360,288 |
24-05-08 | 16.61 | -5.41% | 471,166 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.88% | 813M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- ALXO Stock